FORMULATIONS OF (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE

1 . A solid pharmaceutical formulation for oral delivery of (R)-2-amino-3-phenylpropyl carbamate (APC) consisting of:

i) a pharmaceutically acceptable salt of APC containing 37.5 mg of APC;

ii) a binder in an amount not exceeding 5% by weight of the formulation;

iii) a lubricant in an amount of about 0.1-2% by weight of the formulation; and

iv) an optional coating;

wherein the formulation releases at least 85% of the pharmaceutically acceptable salt of APC in less than 15 minutes after oral administration of the formulation to a subject; and wherein the formulation exhibits substantially identical dissolution rates of the pharmaceutically acceptable salt of APC at pH 1.2, pH 4.5, and pH 6.8;

wherein the binder is selected from hydroxypropyl cellulose, hydroxypropyl methylcellulose, and povidone; and

wherein the lubricant is selected from magnesium stearate, calcium stearate, and sodium stearyl fumarate.

2 . The solid pharmaceutical formulation of claim 1 , wherein the formulation releases at least 95% of the (R)-2-amino-3-phenylpropyl carbamate or a pharmaceutically acceptable salt thereof contained therein within a period of less than 15 minutes after administration of the formulation to a subject.

3 . The solid pharmaceutical formulation of claim 1 , wherein hydroxypropyl cellulose is in an amount of about 1-3% by weight of the formulation.

4 . The solid pharmaceutical formulation of claim 1 , wherein magnesium stearate is in an amount of about 0.1% to about 1.0% by weight of the formulation.

5 . The solid pharmaceutical formulation of claim 1 , wherein (R)-2-amino-3-phenylpropyl carbamate or a pharmaceutically acceptable salt thereof is in an amount of about 90-98% by weight of the formulation;

hydroxypropyl cellulose is in an amount of about 1-5% by weight of the formulation; and

magnesium stearate is in an amount of about 0.1-2% by weight of the formulation.

6 . The solid pharmaceutical formulation of claim 1 , wherein (R)-2-amino-3-phenylpropyl carbamate or a pharmaceutically acceptable salt thereof is in an amount of about 90-98% by weight of the formulation;

hydroxypropyl cellulose is in an amount of about 2% by weight of the formulation; and

magnesium stearate is in an amount of about 0.5% by weight of the formulation.

7 . The solid pharmaceutical formulation of claim 1 , wherein the (R)-2-amino-3-phenylpropyl carbamate or a pharmaceutically acceptable salt thereof is (R)-2-amino-3-phenylpropyl carbamate hydrochloride.

8 . The solid pharmaceutical formulation of claim 1 , wherein the coating is present.

9 . The solid pharmaceutical formulation of claim 8 , wherein the coating is a color overcoat.